ArticleAntibiotics (Basel, Switzerland)2021
Adsorption of Phenazines Produced by
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Mechanisms of synergistic antibacterial and anti-biofilm effects of dihydroquercetin combined with ceftazidime against mucoidFrontiers in microbiology · 2026Article
- Determination of the effect of pyocyanin and Saccharomyces boulardii on gut microbiota and TLR4/MyD88/NF-κB and NLRP3 signaling pathways in sepsis induced by cecal ligation and puncture in rats.BMC infectious diseases · 2025Article
- Synthesis of polypyrrole/cellulose nanocrystals disks for removal of pyocyanin metabolite biomarker released by Pseudomonas aeruginosa.PloS one · 2025Article
- Transforming microbial pigment into therapeutic revelation: extraction and characterization of pyocyanin from Pseudomonas aeruginosa and its therapeutic potential as an antibacterial and anticancer agent.Microbial cell factories · 2024Article
- The Utility of Metagenomic Next-Generation Sequencing (mNGS) in the Management of Patients With Bronchiectasis: A Single-Center Retrospective Study of 93 Cases.Open forum infectious diseases · 2023Article
- A phenazine-inspired framework for identifying biological functions of microbial redox-active metabolites.Current opinion in chemical biology · 2023Review
- Pseudomonas aeruginosa's greenish-blue pigment pyocyanin: its production and biological activities.Microbial cell factories · 2023Review
- Article
- A Macroporous Magnesium Oxide-Templated Carbon Adsorbs Shiga Toxins and Type III Secretory Proteins in EnterohemorrhagicFrontiers in microbiology · 2022Article
- Adsorption of extracellular proteases and pyocyanin produced byCurrent research in microbial sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
AST-120 (Kremezin) is used to treat progressive chronic kidney disease by adsorbing uremic toxin precursors produced by the gut microbiota, such as indole and phenols. Previously, we found that AST-120 decreased drug tolerance and virulence in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.